Tourmaline Bio, Inc. Board of Directors

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

Dr. Sandeep C. Kulkarni M.D.

Dr. Sandeep C. Kulkarni M.D.

Co-Founder, CEO & Director

Mr. Gerhard Hagn Pharm.D.

Mr. Gerhard Hagn Pharm.D.

Senior VP and Head of Commercial & Business Development

Ms. Kimberly Piorkowski

Ms. Kimberly Piorkowski

Vice President of People, Culture & Compliance

Dr. Emil M. deGoma M.D.

Dr. Emil M. deGoma M.D.

Senior Vice President of Medical Research

Dr. Susan Dana Jones Ph.D.

Dr. Susan Dana Jones Ph.D.

Chief Technology Officer

Ms. Dora Rau

Ms. Dora Rau

Senior VP & Head of Quality

Dr. Kristine Erickson O.D., Ph.D.

Dr. Kristine Erickson O.D., Ph.D.

VP & TA Head of Ophthalmology, Medical Research

Mr. W. Bradford Middlekauff J.D.

Mr. W. Bradford Middlekauff J.D.

Chief Business Officer, General Counsel & Corporate Secretary

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.